DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Life Science Investing
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 Life Science Investing
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight Life Science Investing
Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination Life Science Investing
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment Life Science Investing
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data Life Science Investing
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease Life Science Investing
PTC Introduces Onshape Labs to Accelerate AI Inside the Product Development Process Life Science Investing
